ArticleJournal for immunotherapy of cancer2020

Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients.

Jean-Pascal Machiels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.